Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

Abstract: An electrode is provided that is suitable for use with the electrolysis of water in a liquid electrolyte medium, the electrode formulated by the following formulation method: a) dissolving, in a volatile solvent or a mixture of volatile solvents, at least one ion-conducting polymer binder that allows, in the solid state, the diffusion of the gases formed during electrolysis; b) adding, to the solution obtained in step a), at least one electrocatalytic material in the form of divided powder, in order to obtain a mixture; and c) depositing the mixture obtained in step b) on a metallic or metallic-type conductive support or collector, said support or said collector being openwork and chemically stable in an aqueous medium, steps a) and b) being able to be implemented simultaneously, successively or to be reversed.

Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.

Abstract: The invention relates to the use, as an extraction agent for extracting at least one rare earth from an aqueous phase including phosphoric acid, of at least one compound of the following general formula (I): where n is an integer equal to 0, 1 or 2, R1 and R2 are H or an aliphatic hydrocarbon group, one of R3 and R4 has the following formula (II): where R5 and R6 are a hydrocarbon, hydroxyl or alkoxyl group, and the other one of R3 and R4 has one of the following formulas (II?) and (III): where R5? and R6? are a hydrocarbon, hydroxyl or alkoxyl group, and R7 and R8 are H or an aliphatic hydrocarbon group. The invention also relates to a method for recovering at least one rare earth using said compound, as well as to specific compounds as such.

Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.

Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

Abstract: The present invention relates to anti-claudin 1 antibodies for use in the treatment of colorectal cancer. In particular, the present invention relates to a method of treating a colorectal cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an anti-claudin 1 (CLDN1) antibody.

Abstract: The present invention relates to an inhibitor of FXYD2 gene expression for use in a method for treating neuropathic pain in a patient in need thereof. The invention also relates to a pharmaceutical composition comprising an inhibitor of FXYD2 gene expression, wherein said pharmaceutical composition is formulated for a direct administration into the peripheral nervous system (PNS) of a patient (e.g., formulated for intrathecal administration).

Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R? is a hydrogen atom or a (C1-C4)alkyl group; n? is 1 or 2; n is 1, 2, or 3; R independently represents a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —NR1R2 group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a (C1-C3)fluoroalkoxy, and a (C1-C4)alkoxy group; R? is a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a (C1-C4)alkoxy group, and a CN group; R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group; with the proviso that when R and R? are not simultaneously a hydrogen atom: when n is 1, R is not a methyl group in an ortho or para position with respect to N, when R? is a hydrogen atom, R is not a bromine atom or a chlorine atom, and when R is a hydrogen atom, R? is not a methyl or ethyl group, a —COOH group, a —COOC2H5 group, or a bromine atom that

Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.

Abstract: The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

Abstract: Process for the preparation of a vinylidene chloride polymer composite comprising a solid particulate encapsulated in the vinylidene chloride polymer. The process comprises providing a dispersion of a solid particulate material in a liquid phase, said dispersion comprising a RAFT/MADIX agent; providing vinylidene chloride and optionally one or more ethylenically unsaturated monomer copolymerizable therewith to said dispersion; and polymerizing vinylidene chloride and said optionally present one or more ethylenically unsaturated monomer under the control of said RAFT/MADIX agent to form polymer at the surface of said solid particulate material.

Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

Abstract: The invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and of the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.

Abstract: The method for evaluating the compactness of a layer of railroad ballast near a railroad tie includes at least one step of taking at least two measurements (11,11a,11b) of the penetration resistance (Qd) of the ballast (13) near one and the same railroad tie (10), and a step of calculating the mean value (Qdmean) of these measurements (11,11a,11b) of penetration resistance (Qd). Also provided are a device for implementing such a method and a method for predicting the settlement of the ballast of a railroad track including a step of evaluating the compactness of a ballast near a railroad tie.

Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.

Abstract: The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.

Abstract: A laser device is provided for generating an optical wave at a laser frequency, including (i) a semiconductor element having a gain region with quantum wells, the gain region being located between a first mirror and an exit region defining an optical microcavity, (ii) a second mirror distinct from the semiconductor element and arranged so as to form with the first mirror an external optical cavity including the gain region, (iii) a pump for pumping the gain region so as to generate the optical wave, wherein the optical microcavity with the gain region and the external optical cavity are arranged so that a spectral ratio between the Half Width Half Maximum (HWHM) spectral bandwidth of the modal gain and a free spectral range of the external cavity in the range of 2 to 50.

Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.